Recent Updates
Recently added Catalysts
VSTM Positive Sentiment

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Tuesday, September 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Verastem Oncology will present new clinical data for VS-7375, an oral KRAS G12D inhibitor, at an investor event on October 14. The data will focus on its efficacy and safety in treating pancreatic, lung, and colorectal cancers. This presentation is part of the ongoing TARGET-D clinical development program.

Market Sentiment Analysis

POSITIVE FACTORS

  • Verastem is advancing new medicines for RAS/MAPK pathway-driven cancers.
  • Initial efficacy data for VS-7375 shows promise in multiple cancer types.
  • The investor event will provide updated safety and tolerability data.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+156%
120-day peak, hindsight
Typical move
28.1%
average across 4 past catalysts
Cash runway
~9 mo
Medium dilution risk
Lead asset
VS-7375
Phase 1 · Pancreatic Ductal Adenocarcinoma

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical upd

Frequently Asked Questions

What is VS-7375?

VS-7375 is an oral KRAS G12D inhibitor developed by Verastem Oncology.

When will the investor event take place?

The investor event is scheduled for October 14 at 8:00 am ET.

What types of cancer is VS-7375 targeting?

VS-7375 is being studied for pancreatic, lung, and colorectal cancers.

What will be presented at the event?

The event will present initial efficacy and updated safety data for VS-7375.

ShareAdd on Google
Tags: VSTM Viatris Investor Conferences Healthcare Verastem Oncology VS-7375 KRAS G12D pancreatic cancer lung cancer
Last updated: Sep 8, 2026

Biotech snapshot

Cash runway
$136M liquidity · $15M/mo burn
~9 mo
Medium dilution risk
Lead asset
VS-7375Phase 1
Pancreatic Ductal Adenocarcinoma →

Catalyst track record

+156%
best trade around VSTM's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for VSTM.

See every catalyst's timing & PoA →